Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Neurobiol Aging. 2013 Aug 17;35(1):10.1016/j.neurobiolaging.2013.07.013. doi: 10.1016/j.neurobiolaging.2013.07.013

Figure 1.

Figure 1

A) Individual and combined effects of SNCA rs181489, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs181489, the risk genotype was CT or TT (i.e. presence of the minor allele); B) Individual and combined effects of SNCA rs356129, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs356129, the risk genotype was AG or GG (i.e. presence of the minor allele); C) Individual and combined effects of SNCA rs11931074, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs11931074, the risk genotype was GT or TT (i.e. presence of the minor allele); D) Individual and combined effects of SNCA rs2583988, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs2583988, the risk genotype was CT or TT (i.e. presence of the minor allele). Figures 1A–1D) For MAPT rs1052553, the risk genotype was AA (i.e. presence of two copies of the major allele); for LRRK2 p.R1398H, the protective genotype was GA or AA (i.e. presence of the minor allele); NA indicates that a given SNP was not involved in the particular portion of the analysis.